Drug safety check: tracking side effects in new leukemia patients
NCT ID NCT05665374
Summary
This study monitored the safety of Calquence (acalabrutinib) in real-world patients with previously untreated chronic lymphocytic leukemia. It tracked how often side effects like infections and low blood counts occurred after the drug was approved for this use. The goal was to understand the drug's safety profile in everyday medical practice.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKAEMIA (INCLUDING SMALL LYMPHOCYTIC LYMPHOMA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Aichi, Japan
-
Research Site
Chiba, Japan
-
Research Site
Fukuoka, Japan
-
Research Site
Hyōgo, Japan
-
Research Site
Kanagawa, Japan
-
Research Site
Kyoto, Japan
-
Research Site
Miyazaki, Japan
-
Research Site
Nagano, Japan
-
Research Site
Nara, Japan
-
Research Site
Okayama, Japan
-
Research Site
Osaka, Japan
-
Research Site
Saitama, Japan
-
Research Site
Shizuoka, Japan
-
Research Site
Tokyo, Japan
-
Research Site
Yamanashi, Japan
Conditions
Explore the condition pages connected to this study.